Company Description

Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases.

Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation.

The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021.

Skye Bioscience, Inc. is headquartered in San Diego, California.

Skye Bioscience, Inc.

Country	United States
Founded	2012
Industry	Biotechnology
Sector	Healthcare
Employees	12
CEO	Punit Dhillon

Contact Details

Address: 11250 El Camino Real, Suite 100 San Diego, California 92130 United States
Phone	858 410 0266
Website	skyebioscience.com

Stock Details

Ticker Symbol	SKYE
Exchange	NASDAQ
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	1516551
CUSIP Number	83086J101
ISIN Number	US83086J2006
Employer ID	45-0692882
SIC Code	2834

Key Executives

Name	Position
Punit S. Dhillon B.A.	President, Chief Executive Officer and Director
Tu Diep M.Sc.	Chief Operating Officer
John P. Sharp CPA	Chief Financial Officer and Principal Financial and Accounting Officer
Dr. Christopher G. Twitty Ph.D.	Chief Scientific Officer
Dr. Puneet S. Arora FACE, M.D., M.S.	Chief Medical Officer

Latest SEC Filings

Date	Type	Title
Apr 16, 2026	ARS	Filing
Apr 16, 2026	DEFA14A	Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 16, 2026	DEF 14A	Other definitive proxy statements
Apr 6, 2026	PRE 14A	Other preliminary proxy statements
Apr 6, 2026	PREM14A	Filing
Apr 6, 2026	8-K/A	[Amend] Current report
Apr 3, 2026	8-K	Current Report
Mar 19, 2026	8-K	Current Report
Mar 11, 2026	S-8	Securities to be offered to employees in employee benefit plans
Mar 10, 2026	8-K	Current Report

View All SEC Filings